Eli Lilly Abandons Alzheimer's Drug After Failed Trial
Eli Lilly & Co. on Wednesday said it will be shutting down clinical trials for solanezumab, a drug meant to treat mild dementia in Alzheimer's patients, after a phrase-three study showed...To view the full article, register now.
Already a subscriber? Click here to view full article